Wartewig T, Ruland J. PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol. 2019;40(5):403-14. https://doi.org/10.1016/j.it.2019.03.005.

Article  CAS  PubMed  Google Scholar 

Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J Immunother Cancer. 2021;9(10). https://doi.org/10.1136/jitc-2021-002699.

Chaib S, Lopez-Dominguez JA, Lalinde-Gutierrez M, Prats N, Marin I, Boix O, et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat Cancer. 2024;5(3):448-62. https://doi.org/10.1038/s43018-023-00712-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19(5):287-305. https://doi.org/10.1038/s41571-022-00601-9.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. https://doi.org/10.1016/S1470-2045(20)30641-0.

Article  CAS  PubMed  Google Scholar 

Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respiratory Med. 2021;9(5):467-75. https://doi.org/10.1016/S2213-2600(20)30391-X.

Article  CAS  Google Scholar 

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345-62. https://doi.org/10.1038/s41571-021-00473-5.

Article  CAS  PubMed  Google Scholar 

Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in recurrent or metastatic cervical, vaginal, or Vulvar Carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37(31):2825-34. https://doi.org/10.1200/JCO.19.00739.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Escudier B, Mcdermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803-13. https://doi.org/10.1056/NEJMoa1510665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shin SJ, Jeon YK, Kim PJ, Cho YM, Koh J, Chung DH, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell Carcinoma: Association with Oncogenic proteins Status. Ann Surg Oncol. 2016;23(2):694-702. https://doi.org/10.1245/s10434-015-4903-7.

Article  PubMed  Google Scholar 

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015;10(12):1726-35. https://doi.org/10.1097/JTO.0000000000000687.

Article  CAS  PubMed  Google Scholar 

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to Anti-PD-1 therapy in Cancer. Clin Cancer Res. 2017;23(12):3158-67. https://doi.org/10.1158-1078.CCR-16-1761.

Article  CAS  PubMed  Google Scholar 

Li T, Niu M, Zhou J, Wu K, Yi M. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling. Cell Commun Signal. 2024;22(1):179. https://doi.org/10.1186/s12964-024-01562-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang B, Shi J, Shi X, Xu X, Gao L, Li S, et al. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resist Updat. 2024;74:101068. https://doi.org/10.1016/j.drup.2024.101068.

Article  CAS  PubMed  Google Scholar 

Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, et al. A phase 1b study of Ivonescimab, a programmed cell death Protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for Advanced or metastatic immunotherapy-naive NSCLC. J Thorac Oncol. 2024;19(3):465-75. https://doi.org/10.1016/j.jtho.2023.10.014.

Article  CAS  PubMed  Google Scholar 

Touchefeu Y, Bailly C, Frampas E, Eugene T, Rousseau C, Bourgeois M, et al. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study. Eur J Nucl Med Mol Imaging. 2021;48(3):874-82. https://doi.org/10.1007/s00259-020-04989-3.

Article  CAS  PubMed  Google Scholar 

Waaijer SJ, Giesen D, Ishiguro T, Sano Y, Sugaya N, Schroder CP, et al. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2020-000548.

Wang P, Wang S, Liu F, Ren YN, Guo Q, Zhang Q, et al. Preclinical evaluation of a fibroblast activation protein and a prostate-specific membrane Antigen Dual-targeted probe for noninvasive prostate Cancer Imaging. Mol Pharm. 2023;20(2):1415-25. https://doi.org/10.1021/acs.molpharmaceut.2c01000.

Article  CAS  PubMed  Google Scholar 

Yao Y, Hou X, Liu S, Liu T, Ren Y, Ma X, et al. Construction and preclinical evaluation of a (124/125)I-Labeled specific antibody targeting PD-L2 in Lung Cancer. Mol Pharm. 2023;20(2):1365-74. https://doi.org/10.1021/acs.molpharmaceut.2c00958.

Article  CAS  PubMed  Google Scholar 

Yao Y, Ren Y, Hou X, Zhu J, Ma X, Liu S, et al. Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer. Biomed Pharmacother. 2023;168:115602-115602. https://doi.org/10.1016/j.biopha.2023.115602.

Article  CAS  PubMed  Google Scholar 

Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023;50(13):3838-50. https://doi.org/10.1007/s00259-023-06373-3.

Article  CAS  PubMed  Google Scholar 

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, et al. Immune suppression by PD-L2 against spontaneous and treatment-related Antitumor Immunity. Clin Cancer Res. 2019;25(15):4808-19. https://doi.org/10.1158-1078–0432.CCR-18-3991.

Article  CAS  PubMed  Google Scholar 

Youngnak P, Kozono Y, Kozono H, Iwai H, Otsuki N, Jin H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun. 2003;307(3):672-7. https://doi.org/10.1016/s0006-291x(03)01257-9.

Article  CAS  PubMed  Google Scholar 

Wang H, Yao H, Li C, Liang L, Zhang Y, Shi H, et al. PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation. Oncoimmunology. 2017;6(7):e1327494. https://doi.org/10.1080/2162402X.2017.1327494.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer. 2019;7(1):233. https://doi.org/10.1186/s40425-019-0703-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan F, Chen K, Lu X, Li A, Liu C, Wu B. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-mir-194-5p induces immunosuppression in hepatocellular carcinoma. Hepatol Int. 2021;15(2):444-58. https://doi.org/10.1007/s12072-020-10101-6.

Article  PubMed  Google Scholar 

Meng X, Liu H, Li H, Wang S, Sun H, Wang F, et al. Evaluating the impact of different positron emitters on the performance of a clinical PET/MR system. Med Phys (Lancaster). 2022;49(4):2642-51. https://doi.org/10.1002/mp.15513.

Article  CAS  Google Scholar